Should I buy or sell Bellerophon Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLPH, but not buy additional shares or sell existing shares. View BLPH analyst ratings or view top-rated stocks .

What is Bellerophon Therapeutics' stock price target for 2024?

2 brokers have issued 12-month price objectives for Bellerophon Therapeutics' shares. Their BLPH share price targets range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 3,569.7% from the stock's current price. View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts .

How have BLPH shares performed in 2024?

Bellerophon Therapeutics' stock was trading at $0.0370 at the beginning of the year. Since then, BLPH stock has increased by 47.3% and is now trading at $0.0545. View the best growth stocks for 2024 here .

When is Bellerophon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BLPH earnings forecast .

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

When did Bellerophon Therapeutics' stock split?

Bellerophon Therapeutics shares reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , Corbus Pharmaceuticals (CRBP) , Novavax (NVAX) , Pfizer (PFE) , Verastem (VSTM) , Gilead Sciences (GILD) , OPKO Health (OPK) , SCYNEXIS (SCYX) and Dynavax Technologies (DVAX) .

When did Bellerophon Therapeutics IPO?

Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BLPH Stock Alerts

$0.05

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.05
▼
$0.05
50-Day Range: $0.05
▼
$0.06
52-Week Range: $0.03
▼
$11.15

Volume: 1,159 shs
Average Volume: 63,976 shs
Market Capitalization: $666,535.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Get Bellerophon Therapeutics alerts:

Bellerophon Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 3,569.7% Upside
$2.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.86
Upright™ Environmental Score
News Sentiment: 0.69
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Bellerophon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bellerophon Therapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BLPH.

0.0

Dividend Strength

Dividend Yield
Bellerophon Therapeutics does not currently pay a dividend.
Dividend Growth
Bellerophon Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bellerophon Therapeutics has received a 77.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for pulmonary hearth diseases" and "Clinical research services for hypertension" products. See details.
Environmental Sustainability
The Environmental Impact score for Bellerophon Therapeutics is -0.86.

2.6

News and Social Media Coverage

News Sentiment
Bellerophon Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Bellerophon Therapeutics this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Bellerophon Therapeutics is held by insiders.
Percentage Held by Institutions
Only 10.61% of the stock of Bellerophon Therapeutics is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Bellerophon Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bellerophon Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bellerophon Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Bellerophon Therapeutics Stock (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

BLPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLPH Stock News Headlines

April 14, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

February 25, 2024 | uk.finance.yahoo.com

Bellerophon Therapeutics, Inc. (BLPH)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 15, 2024 | investing.com

Bellerophon Therapeutics Inc (BLPH)

January 31, 2024 | msn.com

Bellerophon Offers Series A Stock in Private Sale

November 28, 2023 | benzinga.com

Hilco Streambank Seeks Offers to Acquire Patent Portfolio and Material Inventory of Biotherapeutics Company Bellerophon

November 2, 2023 | morningstar.com

Bellerophon Therapeutics Inc BLPH

August 8, 2023 | finance.yahoo.com

BLPH - Bellerophon Therapeutics, Inc.

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

July 25, 2023 | msn.com

What's Happening With Bellerophon Therapeutics Stock Today?

July 25, 2023 | investorplace.com

Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?

July 6, 2023 | msn.com

Bellerophon Therapeutics (BLPH) Price Target Decreased by 92.23% to 2.04

June 6, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Bellerophon Therapeutics

June 6, 2023 | finance.yahoo.com

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?

June 6, 2023 | msn.com

Laidlaw & Co. Downgrades Bellerophon Therapeutics (BLPH)

June 6, 2023 | msn.com

HC Wainwright & Co. Maintains Bellerophon Therapeutics (BLPH) Buy Recommendation

June 5, 2023 | msn.com

Bellerophon Therapeutics Stock Nosedive: Here's Why

June 5, 2023 | msn.com

Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?

June 5, 2023 | finance.yahoo.com

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

May 19, 2023 | msn.com

Lucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losers

May 17, 2023 | finance.yahoo.com

Bellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week alone

May 16, 2023 | finanznachrichten.de

Bellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

May 15, 2023 | finance.yahoo.com

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

April 28, 2023 | finance.yahoo.com

Bellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should Know

April 24, 2023 | finance.yahoo.com

Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?

April 19, 2023 | finance.yahoo.com

Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know

See More Headlines

Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BLPH
CUSIP: N/A
CIK: 1600132
Web: www.bellerophon.com
Phone: (908) 574-4770
Fax: N/A
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +3,569.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,830,000.00
Net Margins: N/A
Pretax Margin: -186.70%
Return on Equity: -187.35%
Return on Assets: -104.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.96
Quick Ratio: 3.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.27 per share
Price / Book: 0.20

Miscellaneous

Outstanding Shares: 12,230,000
Free Float: 11,597,000
Market Cap: $666,535.00
Optionable: Optionable
Beta: 0.67

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Craig R. Jalbert CIRA (Age 62)
President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

BLPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bellerophon Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLPH, but not buy additional shares or sell existing shares.
View BLPH analyst ratings or view top-rated stocks.
What is Bellerophon Therapeutics' stock price target for 2024?: 2 brokers have issued 12-month price objectives for Bellerophon Therapeutics' shares. Their BLPH share price targets range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 3,569.7% from the stock's current price.
View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts.
How have BLPH shares performed in 2024?: Bellerophon Therapeutics' stock was trading at $0.0370 at the beginning of the year. Since then, BLPH stock has increased by 47.3% and is now trading at $0.0545.
View the best growth stocks for 2024 here.
When is Bellerophon Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our BLPH earnings forecast.
How were Bellerophon Therapeutics' earnings last quarter?: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

When did Bellerophon Therapeutics' stock split?: Bellerophon Therapeutics shares reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Bellerophon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).
When did Bellerophon Therapeutics IPO?: Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.
How do I buy shares of Bellerophon Therapeutics?: Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLPH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

Bellerophon Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Bellerophon Therapeutics Stock (NASDAQ:BLPH)

BLPH Stock Price History

BLPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

BLPH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™